Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Takano T, Fukui T, Ohe Y, et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol. 2008 Dec 1;26(34):5589–5595.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016 Nov 10;375(19):1823–1833.
   PubMed Web of Science ®Google Scholar
• Cooper CS, Park M, Blair DG, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature. 1984 Sep 6-11;311(5981):29–33.
   PubMed Web of Science ®Google Scholar
• Giordano S, Ponzetto C, Di Renzo MF, et al. Tyrosine kinase receptor indistinguishable from the c-met protein. Nature. 1989 May 11;339(6220):155–156.
   PubMed Web of Science ®Google Scholar
• Naldini L, Vigna E, Narsimhan RP, et al. Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene. 1991 Apr;6(4):501–504.
   PubMed Web of Science ®Google Scholar
• Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991 Feb 15;251(4995):802–804.
   PubMed Web of Science ®Google Scholar
• Eder JP, Vande Woude GF, Boerner SA, et al. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res. 2009 Apr 1;15(7):2207–2214.
   PubMed Web of Science ®Google Scholar
• Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more [Review Article]. Nat Rev Mol Cell Biol. 2003 Dec 01;4:915.
   PubMed Web of Science ®Google Scholar
• Okuda K, Sasaki H, Yukiue H, et al. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci. 2008 Nov;99(11):2280–2285.
   PubMed Web of Science ®Google Scholar
• Park S, Choi YL, Sung CO, et al. High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients. Histol Histopathol. 2012 Feb;27(2):197–207.
   PubMed Web of Science ®Google Scholar
• Tsuta K, Kozu Y, Mimae T, et al. c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas. J Thorac Oncol. 2012 Feb 01;7(2):331–339.
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Marchetti A, Skokan M, et al. Increased MET gene copy number negatively affects survival of surgically resected non–small-cell lung cancer patients. J clin oncol. 2009 Apr 01;27(10):1667–1674.
   PubMed Web of Science ®Google Scholar
• Beau-Faller M, Ruppert A-M, Voegeli A-C, et al. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort. J Thorac Oncol. 2008;3(4):331–339.
   PubMed Web of Science ®Google Scholar
• Feng Y, Thiagarajan PS, Ma PC. MET signaling: novel targeted inhibition and its clinical development in lung cancer. J Thorac Oncol. 2012 Feb;7(2):459–467.
   PubMed Web of Science ®Google Scholar
• Schoffski P, Gordon M, Smith DC, et al. Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. Eur J Cancer. 2017 Oct;20(86):296–304.
   Google Scholar
• Scagliotti G, von Pawel J, Novello S, et al. Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015 Aug 20;33(24):2667–2674.
   PubMed Web of Science ®Google Scholar
• Spigel DR, Edelman MJ, O’Byrne K, et al. Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non–small-cell lung cancer: METLung. J clin oncol. 2017 Feb 01;35(4):412–420.
   PubMed Web of Science ®Google Scholar
• Paik PK, Drilon A, Fan PD, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 2015 Aug;5(8):842–849.
   PubMed Web of Science ®Google Scholar
• Jenkins RW, Oxnard GR, Elkin S, et al. Response to crizotinib in a patient with lung adenocarcinoma harboring a MET splice site mutation. Clin Lung Cancer. 2015 Sep;16(5):e101–4.
   PubMed Web of Science ®Google Scholar
• Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015 Aug;5(8):850–859.
   PubMed Web of Science ®Google Scholar
• Waqar SN, Morgensztern D, Sehn J. MET mutation associated with responsiveness to crizotinib. J Thorac Oncol. 2015 May;10(5):e29–31.
   PubMed Web of Science ®Google Scholar
• Lee C, Usenko D, Frampton GM, et al. MET 14 deletion in sarcomatoid non-small-cell lung cancer detected by next-generation sequencing and successfully treated with a MET inhibitor. J Thorac Oncol. 2015 Dec;10(12):e113–4.
   PubMed Web of Science ®Google Scholar
• Liu X, Jia Y, Stoopler MB, et al. Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations. J clin oncol. 2016;34(8):794–802.
   PubMed Web of Science ®Google Scholar
• Awad MM, Oxnard GR, Jackman DM, et al. MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-MET overexpression. J Clin Oncol. 2016 Mar 1;34(7):721–730.
   PubMed Web of Science ®Google Scholar
• Schrock AB, Frampton GM, Suh J, et al. Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations. J Thorac Oncol. 2016 Sep;11(9):1493–1502.
   PubMed Web of Science ®Google Scholar
• Mark M, Awad JKL, Madison R, et al., editor. Characterization of 1,387 NSCLCs with MET exon 14 (METex14) skipping alterations (SA) and potential acquired resistance (AR) mechanisms. J clin oncol. 2020 May 20;38(15_suppl):9511-9511.
   Google Scholar
• Awad MM, Leonardi GC, Kravets S, et al. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. Lung Cancer. 2019 Jul;133:96–102.
   PubMed Web of Science ®Google Scholar
• Sabari JK, Leonardi GC, Shu CA, et al. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Ann Oncol. 2018 Aug 27;29(10):2085–2091.
   PubMed Web of Science ®Google Scholar
• Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019 May 24;30(8):1321–1328.
   Web of Science ®Google Scholar
• Guisier F, Dubos-Arvis C, Vinas F, et al. Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced non small cell lung cancer with BRAF, HER2 or MET mutation or RET-translocation. GFPC 01-2018. J Thorac Oncol. 2020 Jan 13;15(4):628–636.
   Web of Science ®Google Scholar
• Pruis MA, Geurts-Giele WRR, von der TJH, et al. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer. Lung Cancer. 2020 Feb;140:46–54.
   PubMed Web of Science ®Google Scholar
• Schoenfeld AJ, Rizvi H, Bandlamudi C, et al. Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. Ann Oncol. 2020 Feb 6;31(5):599–608.
   PubMed Web of Science ®Google Scholar
• Vuong HG, Ho ATN, Altibi AMA, et al. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis. Lung Cancer. 2018 Sep;123:76–82.
   PubMed Web of Science ®Google Scholar
• Tong JH, Yeung SF, Chan AW, et al. MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis. Clin Cancer Res. 2016 Jun 15;22(12):3048–3056.
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007 May 18;316(5827):1039–1043.
   PubMed Web of Science ®Google Scholar
• Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20932–20937.
   PubMed Web of Science ®Google Scholar
• Chen HJ, Mok TS, Chen ZH, et al. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer. Pathol Oncol Res. 2009 Dec;15(4):651–658.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011 Mar 23;3:75ra26–75ra26.
   PubMed Web of Science ®Google Scholar
• Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013 Apr 15;19(8):2240–2247.
   PubMed Web of Science ®Google Scholar
• Papadimitrakopoulou VA, Wu YL, Han JY, et al. Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study. Ann Oncol. 2018;29:viii741.
   Web of Science ®Google Scholar
• Ramalingam SS, Cheng Y, Zhou C, et al. Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study. Ann Oncol. 2018;29:viii740.
   Google Scholar
• Dagogo-Jack I, Yoda S, Lennerz JK, et al. MET alterations are a recurring and actionable resistance mechanism in ALK-positive lung cancer. Clin Cancer Res. 2020 Feb 21;26(11):2535–2545.
   PubMed Web of Science ®Google Scholar
• Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–594.
   PubMed Web of Science ®Google Scholar
• Lee CC, Yamada KM. Identification of a novel type of alternative splicing of a tyrosine kinase receptor. Juxtamembrane deletion of the c-met protein kinase C serine phosphorylation regulatory site. J Biol Chem. 1994 Jul 29;269(30):19457–19461.
   PubMed Web of Science ®Google Scholar
• Ma PC, Jagadeeswaran R, Jagadeesh S, et al. Functional expression and mutations of c-met and its therapeutic inhibition with SU11274 and small interfering RNA in non–small cell lung cancer. Cancer Res. 2005;65(4):1479.
   PubMed Web of Science ®Google Scholar
• Kong-Beltran M, Seshagiri S, Zha J, et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res. 2006 Jan 01;66(1):283–289.
   PubMed Web of Science ®Google Scholar
• Abella JV, Peschard P, Naujokas MA, et al. Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation. Mol Cell Biol. 2005 Nov;25(21):9632–9645.
   PubMed Web of Science ®Google Scholar
• Gandino L, Longati P, Medico E, et al. Phosphorylation of serine 985 negatively regulates the hepatocyte growth factor receptor kinase. J Biol Chem. 1994;269(3):1815–1820.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014 Jul 31;511(7511): 543–550.
   PubMed Web of Science ®Google Scholar
• Peschard P, Ishiyama N, Lin T, et al. A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation. J Biol Chem. 2004 Jul 9;279(28):29565–29571.
   PubMed Web of Science ®Google Scholar
• Fujino T, Kobayashi Y, Suda K, et al. Sensitivity and resistance of MET exon 14 mutations in lung cancer to eight MET tyrosine kinase inhibitors in vitro. J Thorac Oncol. 2019 Oct 01;14(10):1753–1765.
   PubMed Web of Science ®Google Scholar
• Hu H, Mu Q, Bao Z, et al. Mutational landscape of secondary glioblastoma guides MET-targeted trial in brain tumor. Cell. 2018 Nov 29;175(6):1665–1678 e18.
   PubMed Web of Science ®Google Scholar
• Onozato R, Kosaka T, Kuwano H, et al. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol. 2009 Jan;4(1):5–11.
   PubMed Web of Science ®Google Scholar
• Seo JS, Ju YS, Lee WC, et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res. 2012 Nov;22(11):2109–2119.
   PubMed Web of Science ®Google Scholar
• Vieira T, Antoine M, Ruppert AM, et al. Blood vessel invasion is a major feature and a factor of poor prognosis in sarcomatoid carcinoma of the lung. Lung Cancer. 2014 Aug;85(2):276–281.
   PubMed Web of Science ®Google Scholar
• Yeung SF, Tong JH, Law PP, et al. Profiling of oncogenic driver events in lung adenocarcinoma revealed MET mutation as independent prognostic factor. J Thorac Oncol. 2015 Sep;10(9):1292–1300.
   PubMed Web of Science ®Google Scholar
• Park S, Koh J, Kim DW, et al. MET amplification, protein expression, and mutations in pulmonary adenocarcinoma. Lung Cancer. 2015 Dec;90(3):381–387.
   PubMed Web of Science ®Google Scholar
• Heist RS, Shim HS, Gingipally S, et al. MET exon 14 skipping in non-small cell lung cancer. Oncologist. 2016 Apr;21(4):481–486.
   PubMed Web of Science ®Google Scholar
• Zheng D, Wang R, Ye T, et al. MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer. Oncotarget. 2016;7(27):41691–41702.
   PubMedGoogle Scholar
• Liu SY, Gou LY, Li AN, et al. The unique characteristics of MET exon 14 mutation in Chinese patients with NSCLC. J Thorac Oncol. 2016 Sep;11(9):1503–1510.
   PubMed Web of Science ®Google Scholar
• Saffroy R, Fallet V, Girard N, et al. MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung. Oncotarget. 2017 Jun 27;8(26):42428–42437.
   PubMedGoogle Scholar
• Gow CH, Hsieh MS, Wu SG, et al. A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population. Lung Cancer. 2017 Jan;103:82–89.
   PubMed Web of Science ®Google Scholar
• Jordan EJ, Kim HR, Arcila ME, et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov. 2017 Jun;7(6):596–609.
   PubMed Web of Science ®Google Scholar
• Kwon D, Koh J, Kim S, et al. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: an analysis of intratumoral MET status heterogeneity and clinicopathological characteristics. Lung Cancer. 2017 Apr;106:131–137.
   PubMed Web of Science ®Google Scholar
• Lee GD, Lee SE, Oh DY, et al. MET exon 14 skipping mutations in lung adenocarcinoma: clinicopathologic implications and prognostic values. J Thorac Oncol. 2017 Aug;12(8):1233-1246.
   Web of Science ®Google Scholar
• Suzawa K, Offin M, Lu D, et al. Activation of KRAS mediates resistance to targeted therapy in MET exon 14-mutant non-small cell lung cancer. Clin Cancer Res. 2019 Feb 15;25(4):1248–1260.
   PubMed Web of Science ®Google Scholar
• Lung J, Hung MS, Lin YC, et al. MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population. PLoS One. 2019;14(8):e0220670.
   PubMed Web of Science ®Google Scholar
• Kim EK, Kim KA, Lee CY, et al. Molecular diagnostic assays and clinicopathologic implications of MET exon 14 skipping mutation in non-small-cell lung cancer. Clin Lung Cancer. 2019 Jan;20(1):e123–e132.
   PubMed Web of Science ®Google Scholar
• Kubo T, Yamamoto H, Lockwood WW, et al. MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer. 2009 Apr 15;124(8):1778–1784.
   PubMed Web of Science ®Google Scholar
• Onitsuka T, Uramoto H, Ono K, et al. Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status. J Thorac Oncol. 2010 May 01;5(5):591–596.
   PubMed Web of Science ®Google Scholar
• Okamoto I, Sakai K, Morita S, et al. Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study. Oncotarget. 2014;5(8):2293–2304.
   PubMedGoogle Scholar
• Schildhaus HU, Schultheis AM, Ruschoff J, et al. MET amplification status in therapy-naive adeno- and squamous cell carcinomas of the lung. Clin Cancer Res. 2015 Feb 15;21(4):907–915.
   PubMed Web of Science ®Google Scholar
• Noonan SA, Berry L, Lu X, et al. Identifying the appropriate FISH criteria for defining MET copy number-driven lung adenocarcinoma through oncogene overlap analysis. J Thorac Oncol. 2016 Aug;11(8):1293–1304.
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim HS, Kim BJ. Prognostic value of MET copy number gain in non-small-cell lung cancer: an updated meta-analysis. J Cancer. 2018;9(10):1836–1845.
   PubMed Web of Science ®Google Scholar
• Lutterbach B, Zeng Q, Davis LJ, et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res. 2007 Mar 1;67(5):2081–2088.
   PubMed Web of Science ®Google Scholar
• Tanizaki J, Okamoto I, Okamoto K, et al. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. J Thorac Oncol. 2011 Oct;6(10):1624–1631.
   PubMed Web of Science ®Google Scholar
• Ou S-HI, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) inhibitor, in a non-small cell lung cancer patient with De Novo MET amplification. J Thorac Oncol. 2011 May 01;6(5):942–946.
   PubMed Web of Science ®Google Scholar
• Landi L, Chiari R, Tiseo M, et al. Crizotinib in MET-deregulated or ROS1-rearranged pretreated non-small cell lung cancer (METROS): a phase II, prospective, multicenter, two-arms trial. Clin Cancer Res. 2019 Dec 15;25(24):7312–7319.
   PubMed Web of Science ®Google Scholar
• Moro-Sibilot D, Cozic N, Pérol M, et al. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial. Ann Oncol. 2019;30(12):1985–1991.
   PubMed Web of Science ®Google Scholar
• Caparica R, Yen CT, Coudry R, et al. Responses to crizotinib can occur in high-level MET-amplified non-small cell lung cancer Independent of MET exon 14 alterations. J Thorac Oncol. 2017 Jan;12(1):141–144.
   PubMed Web of Science ®Google Scholar
• Stransky N, Cerami E, Schalm S, et al. The landscape of kinase fusions in cancer. Nat Commun. 2014 Sep 10;5:4846.
   PubMed Web of Science ®Google Scholar
• Cho JH, Ku BM, Sun JM, et al. KIF5B-MET gene rearrangement with robust anti-tumor activity in response to crizotinib in lung adenocarcinoma. J Thorac Oncol. 2018 Mar;13(3):e29-e31.
   Web of Science ®Google Scholar
• Plenker D, Bertrand M, de Langen AJ, et al. Structural alterations of MET trigger response to MET kinase inhibition in lung adenocarcinoma patients. Clin Cancer Res. 2018 Mar15;24(6):1337-1343.
   PubMed Web of Science ®Google Scholar
• Davies KD, Ng TL, Estrada-Bernal A, et al. Dramatic response to crizotinib in a patient with lung cancer positive for an HLA-DRB1-MET gene fusion. JCO Precis Oncol. 2017 Nov 01;(1):1–6. DOI:10.1200/PO.17.00117
   Google Scholar
• Zhu YC, Wang WX, Xu CW, et al. Identification of a novel crizotinib-sensitive MET–ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencing. Ann Oncol. 2018;29(12):2392–2393.
   PubMed Web of Science ®Google Scholar
• Zhu YC, Wang WX, Song ZB, et al. MET-UBE2H fusion as a novel mechanism of acquired EGFR resistance in lung adenocarcinoma. J Thorac Oncol. 2018 Oct;13(10):e202–e204.
   PubMed Web of Science ®Google Scholar
• Pan Y, Zhang Y, Ye T, et al. Detection of novel NRG1, EGFR, and MET fusions in lung adenocarcinomas in the Chinese population. J Thorac Oncol. 2019 Nov;14(11):2003–2008.
   PubMed Web of Science ®Google Scholar
• Lanfang Yu YW, Zhang B, Ma R, et al. Tumor heterogeneity with novel MET fusion showed different response to cabozantinib in non-small cell lung cancer. Int J Clin Exp Med. 2019;12(8):10983–10986.
   Web of Science ®Google Scholar
• Baldacci S, Figeac M, Antoine M, et al. High MET overexpression does not predict the presence of MET exon 14 splice mutations in NSCLC: results from the IFCT Predict.amm study. J Thorac Oncol. 2019 Oct 9;14:S851.
   Web of Science ®Google Scholar
• Watermann I, Schmitt B, Stellmacher F, et al. Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation? Diagn Pathol. 2015 Jul;28(10):130.
   Google Scholar
• Li A, Niu FY, Han JF, et al. Predictive and prognostic value of de novo MET expression in patients with advanced non-small-cell lung cancer. Lung Cancer. 2015 Dec;90(3):375–380.
   PubMed Web of Science ®Google Scholar
• Guo R, Berry LD, Aisner DL, et al. MET IHC is a poor screen for MET amplification or MET exon 14 mutations in lung adenocarcinomas: data from a tri-institutional cohort of the lung cancer mutation consortium. J Thorac Oncol. 2019 Sep;14(9):1666–1671.
   PubMed Web of Science ®Google Scholar
• Chabon JJ, Simmons AD, Lovejoy AF, et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun. 2016 Jun;10(7):11815.
   Google Scholar
• Berger LA, Janning M, Velthaus JL, et al. Identification of a high-level MET amplification in CTCs and cfTNA of an ALK-positive NSCLC patient developing evasive resistance to crizotinib. J Thorac Oncol. 2018 Dec;13(12):e243–e246.
   PubMed Web of Science ®Google Scholar
• Mazzotta M, Filetti M, Rossi A, et al. Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification. Ann Oncol. 2020 Jan 03;31(3):440–441.
   PubMed Web of Science ®Google Scholar
• Gouji T, Takashi S, Mitsuhiro T, et al. Crizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor? J Thorac Oncol. 2014 Mar;9(3):e27–8.
   PubMed Web of Science ®Google Scholar
• Yano S, Wang W, Li Q, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 2008 Nov 15;68(22):9479–9487.
   PubMed Web of Science ®Google Scholar
• Vijayan RS, He P, Modi V, et al. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors. J Med Chem. 2015 Jan 8;58(1):466–479.
   PubMed Web of Science ®Google Scholar
• Cui JJ. Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress. J Med Chem. 2014 Jun 12;57(11):4427–4453.
   PubMed Web of Science ®Google Scholar
• Roskoski R Jr. Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharmacol Res. 2016 Jan;103:26–48.
   PubMed Web of Science ®Google Scholar
• Nolen B, Taylor S, Ghosh G. Regulation of protein kinases; controlling activity through activation segment conformation. Mol Cell. 2004 Sep 10;15(5):661–675.
   PubMed Web of Science ®Google Scholar
• Eathiraj S, Palma R, Volckova E, et al. Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J Biol Chem. 2011 Jun 10;286(23):20666–20676.
   PubMed Web of Science ®Google Scholar
• Katayama R, Aoyama A, Yamori T, et al. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res. 2013 May 15;73(10):3087–3096.
   PubMed Web of Science ®Google Scholar
• Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007 May 1;67(9):4408–4417.
   PubMed Web of Science ®Google Scholar
• Cui JJ, Tran-Dube M, Shen H, et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 2011 Sep 22;54(18):6342–6363.
   PubMed Web of Science ®Google Scholar
• Drilon A, Clark JW, Weiss J, et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat Med. 2020 Jan;26(1):47–51.
   PubMed Web of Science ®Google Scholar
• Liu X, Wang Q, Yang G, et al. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. Clin Cancer Res. 2011 Nov 15;17(22):7127–7138.
   PubMed Web of Science ®Google Scholar
• Baltschukat S, Schacher Engstler B, Huang A, et al. Capmatinib (INC280) is active against models of non-small cell lung cancer and other cancer types with defined mechanisms of MET activation. Clin Cancer Res. 2019 Jan 23;25(10):3164–3175.
   PubMed Web of Science ®Google Scholar
• Edward B, Garon RSH, Seto T, et al., editors. CT082 - capmatinib in METex14-mutated (mut) advanced non-small cell lung cancer (NSCLC): results from the phase II GEOMETRY mono-1 study, including efficacy in patients (pts) with brain metastases (BM). AACR Annual Meeting 2020. 2020 Apr 27.
   Google Scholar
• Wu Y-L, Zhang L, Kim D-W, et al. Phase Ib/II study of capmatinib (INC280) plus gefitinib after failure of Epidermal Growth Factor Receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor–dysregulated non–small-cell lung cancer. J clin oncol. 2018 Nov 01;36(31):3101–3109.
   PubMed Web of Science ®Google Scholar
• Smit EF, Kopp H-G, Kim D-W, et al. GEOMETRY duo-1: a phase (Ph) Ib/II, multicenter trial of oral cMET inhibitor capmatinib (INC280) ± erlotinib vs platinum + pemetrexed in adult patients (pts) with epidermal growth factor receptor (EGFR)-mutated, cMET-amplified, locally advanced/metastatic non-small cell lung cancer (NSCLC) with acquired resistance to prior EGFR tyrosine kinase inhibitor (TKI) therapy. J clin oncol. 2016 June 20;34(15_suppl):TPS9109–TPS9109.
   Web of Science ®Google Scholar
• Bladt F, Faden B, Friese-Hamim M, et al. EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors. Clin Cancer Res. 2013 Jun 1;19(11):2941–2951.
   PubMed Web of Science ®Google Scholar
• Paik PK, Felip E, Veillon R, et al. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med. 2020 May 29. DOI:10.1056/NEJMoa2004407. .
   PubMed Web of Science ®Google Scholar
• Wu Y, Cheng Y, Zhou J, et al. MA09.09 long-term outcomes to tepotinib plus gefitinib in patients with EGFR-mutant NSCLC and MET dysregulation: 18-month follow-up. J Thorac Oncol. 2019;14(10). DOI:10.1016/j.jtho.2019.08.2503
   Web of Science ®Google Scholar
• Yang JCH, Ellers-Lenz B, Straub J, et al. INSIGHT 2: tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study. Ann Oncol. 2019;30:ix181.
   Web of Science ®Google Scholar
• Jia H, Dai G, Weng J, et al. Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2, 3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer. J Med Chem. 2014 Sep 25;57(18):7577–7589.
   PubMed Web of Science ®Google Scholar
• Gavine PR, Ren Y, Han L, et al. Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models. Mol Oncol. 2015 Jan;9(1):323–333.
   PubMed Web of Science ®Google Scholar
• Lu S, Fang J, Cao L, et al. Abstract CT031: preliminary efficacy and safety results of savolitinib treating patients with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations. Cancer Res. 2019;79(13 Supplement):CT031.
   Web of Science ®Google Scholar
• Sequist LV, Han J-Y, Ahn M-J, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020;21(3):373–386.
   PubMed Web of Science ®Google Scholar
• Ahn M, Cantarini M, Frewer P, et al. P1.01-134 SAVANNAH: phase II trial of osimertinib + savolitinib in EGFR-mutant, MET-driven advanced NSCLC, following prior osimertinib. J Thorac Oncol. 2019;14(10):S415–S416.
   Web of Science ®Google Scholar
• Yu H, Goldberg S, Le X, et al. P2.01-22 ORCHARD: a phase II platform study in patients with advanced NSCLC who have progressed on first-line osimertinib therapy. J Thorac Oncol. 2019;14(10):S647.
   Web of Science ®Google Scholar
• Shih J, Zhong B, Shi H, et al. Abstract 2096: bozitinib, a highly selective inhibitor of cMet, demonstrates robust activity in gastric, lung, hepatic and pancreatic in vivo models. Cancer Res. 2017;77(13 Supplement):2096
   Google Scholar
• Ugolini A, Kenigsberg M, Rak A, et al. Discovery and pharmacokinetic and pharmacological properties of the potent and selective MET kinase inhibitor 1-{6-[6-(4-Fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylsulfanyl]benzothiazo l-2-yl}-3-(2-morpholin-4-ylethyl)urea (SAR125844). J Med Chem. 2016 Aug 11;59(15):7066–7074.
   PubMed Web of Science ®Google Scholar
• Angevin E, Spitaleri G, Rodon J, et al. A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification. Eur J Cancer. 2017 Dec;87:131–139.
   PubMed Web of Science ®Google Scholar
• Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011 Dec;10(12):2298–2308.
   PubMed Web of Science ®Google Scholar
• Wang SXY, Zhang BM, Wakelee HA, et al. Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib. Anticancer Drugs. 2019;30(5):537–541.
   PubMed Web of Science ®Google Scholar
• Klempner SJ, Borghei A, Hakimian B, et al. Intracranial activity of cabozantinib in MET exon 14-positive NSCLC with brain metastases. J Thorac Oncol. 2017 Jan;12(1):152–156.
   PubMed Web of Science ®Google Scholar
• D’Arcangelo M, Tassinari D, De Marinis F, et al. P2.01-15 phase II single arm study of cabozantinib in non-small cell lung cancer patients with MET deregulation (CABinMET). J Thorac Oncol. 2019;14(10):2062–2070.
   Web of Science ®Google Scholar
• Yan SB, Peek VL, Ajamie R, et al. LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. Invest New Drugs. 2013 Aug;31(4):833–844.
   PubMed Web of Science ®Google Scholar
• Konicek BW, Capen AR, Credille KM, et al. Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors. Oncotarget. 2018;9(17):13796–13806.
   PubMedGoogle Scholar
• Recondo G, Bahcall M, Spurr LF, et al. Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14 mutant NSCLC. Clin Cancer Res. 2020 Feb 7;26(11):2615–2625..
   Web of Science ®Google Scholar
• Engstrom L, Aranda R, Lee M, et al. Glesatinib exhibits antitumor activity in lung cancer models and patients harboring MET exon 14 mutations and overcomes mutation-mediated resistance to type I MET inhibitors in nonclinical models. Clin Cancer Res. 2017 Aug 01;23(21):6661–6672.
   PubMed Web of Science ®Google Scholar
• Besterman JM, Fournel M, Dupont I, et al. Potent preclinical antitumor activity of MGCD265, an oral Met/VEGFR kinase inhibitor in phase II clinical development, in combination with taxanes or erlotinib. J Clin Oncol. 2010 May 20;28(15_suppl):e13595–e13595.
   Web of Science ®Google Scholar
• Bazhenova L, Kim D-W, Cavanna L, et al. P2.06-017 amethyst NSCLC trial: phase 2 study of MGCD265 in patients with advanced or metastatic NSCLC with activating genetic alterations in MET. J Thorac Oncol. 2017;12(1):S1080–S1081.
   Web of Science ®Google Scholar
• Ai J, Chen Y, Peng X, et al. Preclinical evaluation of SCC244 (Glumetinib), a novel, potent and highly selective inhibitor of c-Met in MET-dependent cancer models. Mol Cancer Ther. 2018 Apr;17(4):751-762.
   Web of Science ®Google Scholar
• Clemenson C, Chargari C, Liu W, et al. The MET/AXL/FGFR inhibitor S49076 impairs aurora B activity and improves the antitumor efficacy of radiotherapy. Mol Cancer Ther. 2017 Oct;16(10):2107–2119.
   PubMed Web of Science ®Google Scholar
• Burbridge MF, Bossard CJ, Saunier C, et al. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab. Mol Cancer Ther. 2013 Sep;12(9):1749–1762.
   PubMed Web of Science ®Google Scholar
• Chang G, Curigliano G, Lim W, et al. MA 12.02 phase I/II study of S49076, a MET/AXL/FGFR inhibitor, combined with gefitinib in NSCLC patients progressing on EGFR TKI. J Thorac Oncol. 2017;12(11):S1847–S1848.
   Web of Science ®Google Scholar
• Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med. 2012;4(120):120ra17.
   PubMed Web of Science ®Google Scholar
• Awad MM, Katayama R, McTigue M, et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med. 2013 Jun 20;368(25):2395–2401.
   PubMed Web of Science ®Google Scholar
• Rotow JK, Gui P, Wu W, et al. Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation-positive lung cancer. Clin Cancer Res. 2020 Jan 15 ;26(2):439-449.
   PubMed Web of Science ®Google Scholar
• Jamme P, Fernandes M, Copin M-C, et al. Alterations in the PI3K pathway drive resistance to MET inhibitors in NSCLC harboring MET exon 14 skipping mutations. J Thorac Oncol. 2020;15(5):741–751.
   Web of Science ®Google Scholar
• Guo R, Offin M, Brannon AR, et al. MET inhibitor resistance in patients with MET exon 14-altered lung cancers. J clin oncol. 2019 May 20;37(15_suppl):9006–9007.
   Google Scholar
• Dong HJ, Li P, Wu CL, et al. Response and acquired resistance to crizotinib in Chinese patients with lung adenocarcinomas harboring MET exon 14 splicing alternations. Lung Cancer. 2016 Dec;102:118–121.
   PubMed Web of Science ®Google Scholar
• Heist RS, Sequist LV, Borger D, et al. Acquired resistance to crizotinib in NSCLC with MET exon 14 skipping. J Thorac Oncol. 2016 Aug;11(8):1242–1245.
   PubMed Web of Science ®Google Scholar
• Ou SI, Young L, Schrock AB, et al. Emergence of preexisting MET Y1230C mutation as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping. J Thorac Oncol. 2017 Jan;12(1):137–140.
   PubMed Web of Science ®Google Scholar
• Schrock AB, Lai A, Ali SM, et al. Mutation of MET Y1230 as an acquired mechanism of crizotinib resistance in NSCLC with MET exon 14 skipping. J Thorac Oncol. 2017;12(7):e89–e90.
   PubMedGoogle Scholar
• Zhang Y, Yin J, Peng F. Acquired resistance to crizotinib in advanced lung adenocarcinoma with MET exon 14 skipping. Lung Cancer. 2017 Nov;113:69–71.
   PubMed Web of Science ®Google Scholar
• Jin W, Shan B, Liu H, et al. Acquired mechanism of crizotinib resistance in NSCLC with MET exon 14 skipping. J Thorac Oncol. 2019 May 2;14(7):e137-e139.
   PubMed Web of Science ®Google Scholar
• Bahcall M, Awad MM, Sholl LM, et al. Amplification of wild-type KRAS imparts resistance to crizotinib in MET exon 14 mutant non-small cell lung cancer. Clin Cancer Res. 2018 Dec 1;24(23):5963–5976.
   PubMed Web of Science ®Google Scholar